Enzymes are immobilized through binding to inert resins, allowing for easier separation from a reaction mixture, and immobilization often allows for the use of these enzymes under different conditions and re-use at a commercial scale. The collaboration will enable Purolite and Codexis to develop immobilized transaminase enzymes for use in the production of pharmaceuticals.
“We have selected Purolite as a partner for immobilization based on their experience with support resins and their ability to supply those resins at every scale,” said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. “Under this new collaboration with Purolite, we will be launching a kit of immobilized transaminases as an extension of our CODEX® Screening Kits. The new immobilized enzyme kits will allow potential customers to quickly assess ideas for biocatalytic processes.”
“We are very proud to partner with Codexis,” said Dr. Alessandra Basso, Business Manager of the LifeTech™ unit at Purolite. “The successful implementation of these ready-to-use immobilized enzymes for fast screening processes opens the door to new concepts of drug development, where scientists who are unfamiliar with biocatalytic processes can easily apply immobilized enzymes to different screening processes that can speed up new-molecule and API development.”